Stock DIA DIASORIN S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials DiaSorin S.p.A.

Equities

DIA

IT0003492391

Medical Equipment, Supplies & Distribution

Market Closed - Borsa Italiana
Other stock markets
 11:44:59 2024-04-26 am EDT 		5-day change 1st Jan Change
94.9 EUR +1.32% Intraday chart for DiaSorin S.p.A. +4.08% +1.78%
Apr. 24 Citadel Advisors initiates short on STMicroelectronics. AN
Apr. 23 Reduced a short on DiaSorin, increased on STM. AN

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,315 9,289 9,163 6,962 4,969 5,064 - -
Enterprise Value (EV) 1 6,142 8,984 10,149 7,868 4,969 5,705 5,533 5,338
P/E ratio 36.1 x 37.5 x 31 x 31.4 x - 29.5 x 24.8 x 21.1 x
Yield 0.82% 0.59% 0.63% 0.84% - 0.99% 1.1% 1.2%
Capitalization / Revenue 8.94 x 10.5 x 7.4 x 5.11 x 4.33 x 4.29 x 3.98 x 3.69 x
EV / Revenue 8.7 x 10.2 x 8.2 x 5.78 x 4.33 x 4.83 x 4.35 x 3.89 x
EV / EBITDA 22.2 x 23.3 x 18.7 x 15.3 x 13.2 x 14.9 x 12.9 x 11.1 x
EV / FCF 34.1 x 38.8 x 33.7 x 24.9 x - 26.9 x 23.3 x 19.3 x
FCF Yield 2.93% 2.58% 2.96% 4.02% - 3.72% 4.3% 5.17%
Price to Book 7.61 x 9.74 x 6.71 x 4.56 x - 3.01 x 2.82 x 2.86 x
Nbr of stocks (in thousands) 54,723 54,608 54,719 53,388 53,289 53,365 - -
Reference price 2 115.4 170.1 167.4 130.4 93.24 94.90 94.90 94.90
Announcement Date 3/11/20 3/11/21 3/16/22 3/27/23 3/15/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 706.3 881.3 1,238 1,361 1,148 1,180 1,272 1,373
EBITDA 1 276.8 385.3 543.1 514.2 375 382.9 427.7 479.5
EBIT 1 217.9 324.2 465.1 417 283 264.8 307.9 357.2
Operating Margin 30.85% 36.79% 37.58% 30.64% 24.65% 22.44% 24.2% 26.02%
Earnings before Tax (EBT) 1 216.3 321.4 399.3 325.9 201 229.3 281.5 327.1
Net income 1 175.7 248.3 310.7 240.1 159 185.8 214.7 247.2
Net margin 24.88% 28.17% 25.1% 17.64% 13.85% 15.74% 16.88% 18.01%
EPS 2 3.200 4.534 5.400 4.150 - 3.212 3.821 4.494
Free Cash Flow 1 180.1 231.6 300.7 316 - 212.3 237.8 276.1
FCF margin 25.5% 26.28% 24.3% 23.22% - 17.99% 18.69% 20.11%
FCF Conversion (EBITDA) 65.07% 60.11% 55.37% 61.45% - 55.45% 55.59% 57.59%
FCF Conversion (Net income) 102.5% 93.27% 96.78% 131.61% - 114.27% 110.75% 111.68%
Dividend per Share 2 0.9500 1.000 1.050 1.100 - 0.9411 1.045 1.142
Announcement Date 3/11/20 3/11/21 3/16/22 3/27/23 3/15/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 356 382.3 515.4 343.5 378.8 357.6 327.8 685.4 326.8 348.8 289.6 286.8 576.4 270 302 272.7 329.1 317.6 282.3 256.2
EBITDA 1 - 153.6 244.2 139.2 159.9 149.8 119.3 269.1 122.1 123 97.5 92.5 190 88 97 93.51 97.61 97.64 108.3 -
EBIT 1 - 123.6 201.9 112.2 151 126.2 95.17 221.4 97.3 98.3 74.8 69.6 144.4 - 74 60.94 75.33 74.34 65.84 65.94
Operating Margin - 32.33% 39.17% 32.66% 39.86% 35.29% 29.03% 32.3% 29.77% 28.18% 25.83% 24.27% 25.05% - 24.5% 22.35% 22.89% 23.41% 23.33% 25.74%
Earnings before Tax (EBT) - 122.2 196.1 103.6 99.5 106.2 75.58 181.8 80.1 64 54.5 - - - 56 - - - - -
Net income 1 - 94.7 150 79.3 81.4 82.3 58.51 140.8 62.1 37.2 41.7 45.1 86.9 - 47 50.26 50.33 47.91 58.23 -
Net margin - 24.77% 29.1% 23.09% 21.49% 23.01% 17.85% 20.54% 19% 10.67% 14.4% 15.73% 15.08% - 15.56% 18.43% 15.29% 15.08% 20.63% -
EPS 2 - - - - 1.490 1.470 1.090 - 1.150 - - - - - - 0.7571 0.9108 0.8874 0.8302 -
Dividend per Share 2 - - - - - - - - - - - - - - - 0.2397 0.3596 0.3596 0.2397 0.2509
Announcement Date 3/11/20 7/30/20 7/30/21 11/11/21 3/16/22 5/6/22 8/3/22 8/3/22 10/27/22 3/27/23 5/9/23 7/27/23 7/27/23 11/3/23 3/15/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 986 907 - 641 469 274
Net Cash position 1 173 305 - - - - - -
Leverage (Debt/EBITDA) - - 1.815 x 1.763 x - 1.674 x 1.097 x 0.5713 x
Free Cash Flow 1 180 232 301 316 - 212 238 276
ROE (net income / shareholders' equity) 22.6% 27.5% 26.7% 16.6% - 12.5% 12.7% 13.7%
ROA (Net income/ Total Assets) - 21.5% 15.9% - - - - -
Assets 1 - 1,157 1,949 - - - - -
Book Value Per Share 2 15.20 17.50 25.00 28.60 - 31.50 33.60 33.20
Cash Flow per Share 2 4.250 5.560 7.010 6.740 - 5.670 6.050 6.840
Capex 1 52.2 73 117 114 - 107 106 109
Capex / Sales 7.39% 8.28% 9.48% 8.35% - 9.1% 8.3% 7.95%
Announcement Date 3/11/20 3/11/21 3/16/22 3/27/23 3/15/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for DiaSorin S.p.A.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
94.9 EUR
Average target price
97.41 EUR
Spread / Average Target
+2.64%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.78% 5.41B
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
-5.02% 1.64B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. DIA Stock
  4. Financials DiaSorin S.p.A.